FDA Approval Alert: The Need-to-Know | Betibeglogene Autotemcel for Transfusion-Dependent Beta-Thalassemia

In August 2022, the FDA approved betibeglogene autotemcel for adult and pediatric patients with β-thalassemia who need regular red blood cell infusions.

Alexis A. Thompson, MD, MPH, Considers Future Assessments of Beti-Cel in β-Thalassemia
Alexis A. Thompson, MD, MPH, Considers Future Assessments of Beti-Cel in β-Thalassemia
Video
Aug 26, 2022 8:00 PM
Alexis A. Thompson, MD, MPH, reviewed the unmet needs of patients with β-thalassemia who will receive betibeglogene autotemcel.
Alexis A. Thompson, MD, MPH, Assesses the Need for Beti-Cel in β-Thalassemia
Alexis A. Thompson, MD, MPH, Assesses the Need for Beti-Cel in β-Thalassemia
Video
Aug 20, 2022 6:00 PM
Alexis A. Thompson, MD, MPH, reviewed unmet needs for patients with β-thalassemia who may now receive betibeglogene autotemcel.
Alexis A. Thompson, MD, MPH, Reviews Approval of Beti-Cel for β-Thalassemia
Alexis A. Thompson, MD, MPH, Reviews Approval of Beti-Cel for β-Thalassemia
Video
Aug 17, 2022 9:00 PM
Alexis A. Thompson, MD, MPH, spoke about the use of betibeglogene autotemcel for patients with β-thalassemia.
FDA Approves Beti-Cel in Transfusion-Dependent β-Thalassemia in Pediatrics and Adults
FDA Approves Beti-Cel in Transfusion-Dependent β-Thalassemia in Pediatrics and Adults
Article
Aug 17, 2022 6:48 PM
Pediatric and adult patients who have β -thalassemia and need regular red blood cell infusions may now receive betibeglogene autotemcel, which has been approved by the FDA.